"139"^^ . . . . "4684"^^ . "Sucampo Pharmaceuticals, Inc."@en . "Andrew P. Smith"@en . "1.8E7"^^ . "5.2E8"^^ . . "2.3E8"^^ . . "2018-02-12"^^ . . . "Acquired byMallinckrodt"@en . . "44919158"^^ . . . . . . . . . . . . . . . . . "Sucampo Pharmaceuticals, Inc."@en . . . "Sucampo Pharmaceuticals, Inc. was a pharmaceutical company headquartered in Rockville, Maryland that focused on gastroenterology, ophthalmology, and oncology-related disorders. In 2018, the company was acquired by Mallinckrodt."@en . "1.67E8"^^ . "2.3E8"^^ . "1996"^^ . . . "5.2E8"^^ . "2018-02-12"^^ . "Sucampo Pharmaceuticals"@en . . . . . . . . . . . . . . . "1.8E7"^^ . . . "1.67E8"^^ . . . "Peter Greenleaf"@en . "Sucampo Pharmaceuticals, Inc. was a pharmaceutical company headquartered in Rockville, Maryland that focused on gastroenterology, ophthalmology, and oncology-related disorders. In 2018, the company was acquired by Mallinckrodt. Sucampo had two marketed products, Amitiza, which treats constipation issues and Rescula, which helps treat ocular hypertension and open-angle glaucoma. Takeda Pharmaceutical Company had a license to distribute Rescula globally except for in Japan and China. The company had two Phase III drugs in development for rare diseases \u2014 one for Niemann-Pick Type C and the other for familial adenomatous polyposis, which can cause colon cancer if untreated."@en . . . . . . . . "Acquired by Mallinckrodt"@en . . . . . . . . . . . "139"^^ . . . "1069885155"^^ . . .